Savant Capital LLC Has $241,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Savant Capital LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,981 shares of the medical equipment provider’s stock after selling 248 shares during the period. Savant Capital LLC’s holdings in Zimmer Biomet were worth $241,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Naples Money Management LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at about $35,000. Activest Wealth Management boosted its stake in Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 275 shares in the last quarter. Peoples Bank KS acquired a new stake in Zimmer Biomet in the third quarter valued at about $48,000. Blue Trust Inc. raised its position in Zimmer Biomet by 48.4% in the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 153 shares during the last quarter. Finally, Quent Capital LLC raised its position in Zimmer Biomet by 21.6% in the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 92 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Evercore ISI increased their target price on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Oppenheimer increased their target price on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday. Citigroup increased their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Finally, Truist Financial lowered their price objective on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research report on Friday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $135.40.

Zimmer Biomet Trading Down 0.9 %

Shares of Zimmer Biomet stock opened at $120.57 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $147.50. The stock has a 50 day moving average price of $125.17 and a two-hundred day moving average price of $120.32. The stock has a market capitalization of $24.80 billion, a PE ratio of 26.10, a price-to-earnings-growth ratio of 2.23 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the firm posted $1.89 earnings per share. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were paid a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.70% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.